Incremental data revealed at the conference could give Mirati, Exelixis and Seattle Genetics renewed hope.
The meeting’s abstracts point to studies from Merck & Co, Exelixis and others that should be on investors’ radar.
For $3m Verastem adds to its pipeline another asset that a bigger company had given up on.
Like AMG 510, MRTX849 yields partial responses in some lung and colorectal tumours, but investors could have expected better.
Mirati pulls a rabbit out of its hat, but the conference will serve up three new competitors too.
The biotech calendar’s next key conference gets under way in a month, and a presentation by Nextcure will be a focus for some investors.
Amgen’s AMG 510 disappoints Kras bulls, showing just two new partial responses, in colorectal and appendiceal tumours.
The latest cut of data from a trial of Amgen’s closely watched Kras inhibitor AMG 510 contains more encouraging signals in lung cancer, though some of the loftiest hopes…
Among small-molecule approaches Europe’s premier oncology conference gives star billing to three Parp inhibitors in ovarian cancer.